Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Meet the Cure Team Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Cure Symposium Calendar

Andrew Stamford, Ph.D.

Andrew (Andy) Stamford, Ph.D., is a Vice President, Chemistry, Deerfield Discovery and Development, and joined the Firm in 2020. Prior to Deerfield, Dr. Stamford spent over three years at Bridge Medicines as Vice President, Chemistry, and then as Senior Vice President of Research and Development. During this time, he also served as Vice President, Chemistry at the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). Dr. Stamford has over 25 years of combined experience at Merck and Schering-Plough Research Institute working in small molecule drug discovery from hit-to-lead to clinical candidate.  He is the co-author of more than 70 peer-reviewed publications and an inventor on over 100 issued US patents. Dr. Stamford holds a B.Sc. in Organic Chemistry from University of Tasmania and a Ph.D. in Organic Chemistry from University of Sydney.